Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00012155 · ClinicalTrials.gov registry record · Phase 1

Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

A Phase 1 study of Colorectal Cancer and Metastatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00012155 is a Phase 1 study of Colorectal Cancer and Metastatic Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00012155, a Phase 1 study of Colorectal Cancer and Metastatic Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to previous chemotherapy.

Interventions

  • BIOLOGICAL NV1020

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Start Date 2000-10
Est. Completion 2009-12
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00012155

The ClinicalTrials.gov registry entry for NCT00012155 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which NV1020 is the first listed.

NCT00012155 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00012155 about?

NCT00012155 is a clinical study titled "Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver". RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to previous chemotherapy.

What is the current status of trial NCT00012155?

This trial is currently completed. It is a Phase 1 study. The study started on 2000-10. Estimated completion is 2009-12.

What conditions does trial NCT00012155 study?

This clinical trial studies the following conditions: Colorectal Cancer, Metastatic Cancer.

What interventions are being tested in trial NCT00012155?

The interventions under investigation include: NV1020 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00012155?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00012155 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.